• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CAREFUSION ALARIS INFUSION SET; SET, ADMINISTRATION, INTRAVASCULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CAREFUSION ALARIS INFUSION SET; SET, ADMINISTRATION, INTRAVASCULAR Back to Search Results
Model Number 10011301
Device Problems Obstruction of Flow (2423); Difficult or Delayed Activation (2577)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 03/15/2019
Event Type  Injury  
Manufacturer Narrative
Concomitant medical products- 100 ml hospira ndc 0409-7984-3,7 lot: 95-110-jt, exp: 1 nov 2020, 0.9% sodium chloride injection.Report source-effectiveness manager.The customer¿s report of occlusion was confirmed and replicated on both returned primary sets.No abnormalities were noted upon visual inspection.Functional testing observed that the fluid would not flow through the sets during priming.Microscopic inspection of the engagement between the check valve inlet port and the tubing (attached by pvc tubing, p/n 660134) identified an obstruction caused by excessive solvent; which created the inability to prime the sets.The reported issue of inability to prime was identified as an occlusion at the engagement between the set¿s check valve p/n: 630110 inlet port and tubing p/n: 605962-000.The root cause for the occlusion was excessive solvent applied during the manufacturing process.
 
Event Description
It was reported that when the nurse attempted to prime two pcea sets with normal saline on the same patient in the pacu, an occlusion was noted on both lines.The patient developed increased pain and required an unspecified dose of iv dilaudid due to the occlusions and delay of therapy.The clinician obtained a 3rd pcea set which primed without difficulty.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ALARIS INFUSION SET
Type of Device
SET, ADMINISTRATION, INTRAVASCULAR
Manufacturer (Section D)
CAREFUSION
10020 pacific mesa blvd
san diego CA 92121 4386
Manufacturer (Section G)
CAREFUSION
10020 pacific mesa blvd
san diego CA 92121 4386
Manufacturer Contact
sylvia ventura
10020 pacific mesa blvd
san diego, CA 92121-4386
8586172000
MDR Report Key8499574
MDR Text Key141466299
Report Number9616066-2019-00918
Device Sequence Number1
Product Code FPA
UDI-Device Identifier10885403232541
UDI-Public10885403232541
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K931173
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date 03/18/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/10/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date10/10/2020
Device Model Number10011301
Device Catalogue Number10011301
Device Lot Number17105892
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer03/22/2019
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured10/10/2017
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
THERAPY DATE: (B)(6) 2019
Patient Outcome(s) Required Intervention;
-
-